Print

Impax Pharmaceuticals Completes Enrollment in ASCEND-PD Phase III Trial of IPX066 in Parkinson’s Disease  
7/26/2011 7:07:15 AM

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment in the ASCEND-PD trial. ASCEND-PD is a multinational Phase III comparative study of IPX066 to carbidopa-levodopa and entacapone in subjects with advanced Parkinson’s disease (PD). IPX066 is an investigational extended release capsule formulation of carbidopa-levodopa (CD-LD) intended to treat the motor symptoms of Parkinson’s disease. IPX066 is being developed in collaboration with GlaxoSmithKline (GSK) outside the US and Taiwan.
//-->